Kiadis Pharma Stock

Kiadis Pharma Dividend 2024

Kiadis Pharma Dividend

0 EUR

Kiadis Pharma Dividend yield

Ticker

KDS.AS

ISIN

NL0011323407

WKN

A14VE3

How much dividend does Kiadis Pharma 2024 pay?

According to the latest status from December 2024, Kiadis Pharma paid a total of 0 EUR per share in dividends within the last 12 months. With the current Kiadis Pharma price of 0 EUR, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Kiadis Pharma Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Kiadis Pharma Dividend Safe?

Kiadis Pharma has been increasing the dividend for 0 years.

Over the past 9 years, Kiadis Pharma has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Kiadis Pharma's Dividend Distributions

Kiadis Pharma’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Kiadis Pharma's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Kiadis Pharma's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Kiadis Pharma’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Kiadis Pharma Aktienanalyse

What does Kiadis Pharma do?

Kiadis Pharma NV was founded in 1997 in Amsterdam and is an innovative biotechnology company specializing in the development of cell therapies for the treatment of blood cancer diseases. The company is based in the Netherlands and is listed on the Euronext Amsterdam stock exchange. The business model of Kiadis is based on the development of therapies for patients with high medical needs, especially for individuals with severe blood cancer diseases for which there are no cure options. The company employs a proprietary platform technology that is based on the activation of T-cells for the therapy of cancer patients. Kiadis is currently developing various therapeutic approaches for the treatment of blood cancer diseases such as leukemia, lymphoma, and multiple myeloma. The company's main products are ATIR101 and ATIR201. ATIR101 is a cell therapy for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) who require an allogeneic stem cell transplant. This therapy aims to reduce the risk of transplant rejection and graft-versus-host disease (GVHD), thereby increasing patients' chances of survival. ATIR201 is a therapy for the treatment of patients with multiple myeloma who require an allogeneic stem cell transplant. This therapy aims to reduce the risks of transplant rejection and GVHD, thereby increasing patients' chances of survival. Kiadis has also developed another platform technology called CytoSen, which is based on the activation of NK cells for the immunotherapy of cancer. The CytoSen technology aims to enhance the effectiveness of T-cell therapy by combining it with NK cells. Kiadis is continuously working to improve and expand its products and therapies. The company has a strong pipeline of product candidates at various stages of development targeting the treatment of leukemia, lymphoma, multiple myeloma, and other cancer diseases. The company has also entered into a partnership with Sanofi to accelerate the development of its therapies. Overall, Kiadis Pharma NV has an impressive history as an innovative company with a clear focus on the development of cell therapies for the treatment of blood cancer diseases. The company is dedicated to improving the lives of cancer patients and continuously works on the development of new therapies to improve the chances of survival and quality of life for cancer patients worldwide. Kiadis Pharma is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Kiadis Pharma stock can be added to a savings plan with the following providers: Trade Republic

Frequently Asked Questions about Kiadis Pharma stock

How much dividend does Kiadis Pharma pay?

Over the past 12 months, Kiadis Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiadis Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Kiadis Pharma?

The current dividend yield of Kiadis Pharma is .

When does Kiadis Pharma pay dividends?

Kiadis Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiadis Pharma?

Kiadis Pharma paid dividends every year for the past 0 years.

What is the dividend of Kiadis Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiadis Pharma located?

Kiadis Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiadis Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiadis Pharma from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Kiadis Pharma pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Kiadis Pharma in the year 2023?

In the year 2023, Kiadis Pharma distributed 0 EUR as dividends.

In which currency does Kiadis Pharma pay out the dividend?

The dividends of Kiadis Pharma are distributed in EUR.

Andere Kennzahlen von Kiadis Pharma

Our stock analysis for Kiadis Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiadis Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.